Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...
Live updates: Trump to discuss tariffs with officials from Canada and Mexico
Trump's wide-ranging tariffs on Mexico, Canada and China divided lawmakers and world leaders over the weekend. President ...
BioNTech Completes Acquisition of Biotheus
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...